Zai Lab Q3 net product revenue rises 47% YoY to $101.8M; KarXT bridging study positive

Zai Lab Ltd

2024-Q3 EPS reported -$0.18 revenue$289,918,000

Net product revenue $101.8M, up 47% YoY; net loss $41.7M ($0.42/ADS loss).
VYVGART sales $27.3M (vs $4.9M YoY); ZEJULA $48.2M (+16%); NUZYRA $10.0M (+82%).
KarXT bridging study in schizophrenia met primary endpoint (9.2-point PANSS reduction, p=0.0014); NDA submission expected early 2025.
ZL-1310 (DLL3 ADC) Phase 1 data shows 74% ORR in extensive-stage SCLC; potential best-in-class.
Cash position $716.1M; three product launches in China expected by end of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.